Literature DB >> 21351292

Continual reassessment and related designs in dose-finding studies.

Alexia Iasonos, John O'Quigley.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21351292      PMCID： PMC3740341          DOI： 10.1002/sim.4215

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  15 in total

1.  An evaluation of phase I clinical trial designs in the continuous dose-response setting.

Authors:  B E Storer
Journal:  Stat Med       Date:  2001-08-30       Impact factor: 2.373

2.  Translation of innovative designs into phase I trials.

Authors:  André Rogatko; David Schoeneck; William Jonas; Mourad Tighiouart; Fadlo R Khuri; Alan Porter
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

3.  Improved designs for dose escalation studies using pharmacokinetic measurements.

Authors:  S Piantadosi; G Liu
Journal:  Stat Med       Date:  1996-08-15       Impact factor: 2.373

4.  An evaluation of phase I cancer clinical trial designs.

Authors:  C Ahn
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  Bayesian decision procedures based on logistic regression models for dose-finding studies.

Authors:  J Whitehead; D Williamson
Journal:  J Biopharm Stat       Date:  1998-07       Impact factor: 1.051

6.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

7.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

8.  Accrual strategies for phase I trials with delayed patient outcome.

Authors:  P F Thall; J J Lee; C H Tseng; E H Estey
Journal:  Stat Med       Date:  1999-05-30       Impact factor: 2.373

9.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

10.  A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.

Authors:  Alexia Iasonos; Andrew S Wilton; Elyn R Riedel; Venkatraman E Seshan; David R Spriggs
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486
View more
  7 in total

Review 1.  Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

2.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Authors:  Ying Yuan; Kenneth R Hess; Susan G Hilsenbeck; Mark R Gilbert
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

3.  A nonparametric Bayesian method for dose finding in drug combinations cancer trials.

Authors:  Zahra S Razaee; Galen Cook-Wiens; Mourad Tighiouart
Journal:  Stat Med       Date:  2022-01-25       Impact factor: 2.373

4.  Adaptive prior variance calibration in the Bayesian continual reassessment method.

Authors:  Jin Zhang; Thomas M Braun; Jeremy M G Taylor
Journal:  Stat Med       Date:  2012-09-17       Impact factor: 2.373

5.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.

Authors:  Suyu Liu; Guosheng Yin; Ying Yuan
Journal:  Ann Appl Stat       Date:  2013-12-01       Impact factor: 2.083

6.  Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.

Authors:  Gareth D James; Stefan N Symeonides; Jayne Marshall; Julia Young; Glen Clack
Journal:  BMC Cancer       Date:  2016-08-31       Impact factor: 4.430

7.  Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.

Authors:  G D James; S Symeonides; J Marshall; J Young; G Clack
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.